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Abstract
The signal transduction events which govern major histocompatibility complex-unrestricted tumour cell destruction by
nonspecific killer T lymphocytes induced with anti-CD3 antibody have not yet been determined. In this study we used
 .  .pharmacologic inhibitors to investigate the role of protein tyrosine kinases PTK and protein kinase C PKC in this
process. The PTK-inhibitors herbimycin A, genistein, and methyl 2,5-dihydroxycinnamate blocked anti-CD3-activated killer
 .T AK-T lymphocyte-mediated killing of tumour target cells. The PKC-inhibitors staurosporine, calphostin C, and
myristoylated PKC pseudosubstrate peptide, as well as PKC desensitization by phorbol 12-myristate 13-acetate pretreat-
ment, also suppressed the cytolytic effector function of AK-T lymphocytes. Lack of tumoricidal activity was not due to
reduced AK-T lymphocyte binding to tumour target cells but was associated with the abrogation of granule exocytosis,
indicating that PTK and PKC are involved in the postbinding process which results in delivery of the ‘lethal hit’ by AK-T
lymphocytes. q 1997 Elsevier Science B.V. All rights reserved.
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1. Introduction
Activation of human and murine T lymphocytes
 .with anti-CD3 monoclonal antibody mAb results in
the generation of major histocompatibility complex-
Abbreviations: AK-T, anti-CD3-activated killer T; BLT, Na-
CBZ-L-lysine thiobenzylester; CTL, cytotoxic T lymphocyte;
DMSO, dimethyl sulfoxide; E:T, effector:target; mAb, mono-
clonal antibody; MDHC, methyl 2,5-dihydroxycinnamate; MTT,
 .3- 4,5-dimethylthiazol-2-yl -2,5-diphenyltetrazolium bromide;
myr-c PKC, myristoylated protein kinase C pseudosubstrate pep-
tide; NK, natural killer; PKC, protein kinase C; PMA, phorbol
12-myristate 13-acetate; PTK, protein tyrosine kinase.
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unrestricted killer T lymphocytes with nonspecific
cytolytic activity against a range of tumour target
w xcells 1–3 . Although little is known about how anti-
 .CD3-activated killer T AK-T lymphocytes target
tumour cells for cytolysis, recognition of tumour cells
by AK-T lymphocytes apparently does not involve
the T cell receptorrCD3 complex since these anti-
gen-receptor complexes are rapidly modulated off the
T cell-surface following exposure to anti-CD3 mAb
w x4,5 . Rather, the ability of AK-T lymphocytes to
 .recognize and lyse natural killer NK cell-resistant,
as well as NK-sensitive tumour target cells but not
w xuntransformed cells 3,6 suggests that tumour recog-
nition by AK-T lymphocytes may involve a receptor
similar to the putative tumour recognition structure
employed by other major histocompatibility
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 .complex-unrestricted cytotoxic T lymphocytes CTL
w xand NK-derived lymphokine activated killer cells 7 .
T lymphocyte activation through the T cell recep-
torrCD3 complex, such as occurs following stimula-
tion with specific antigen or anti-CD3 mAb, involves
the activation of several distinct intracellular protein
 . w x 2qtyrosine kinases PTK 8 , release of Ca from
intracellular stores and the activation of protein ki-
 . 2qnase C PKC which is a phospholipidrCa -sensi-
w w xxtive protein serinerthreonine kinase reviewed in 9 .
Sustained PKC activation in combination with in-
creased intracellular free Ca2q levels promotes the
expression of several nuclear regulatory DNA-bind-
ing proteins and the induction of genes required for T
w w xxcell proliferation and differentiation reviewed in 10 .
w xIn a recent study Ting et al. 11 have shown that the
pathway for AK-T lymphocyte induction which leads
to the expression of cytolytic perforin and granzyme
molecules is dependent on PKC activity but has a
less stringent requirement for PTK activation. How-
ever, the requirement for PKC andror PTK activa-
tion to trigger cytolytic effector function by AK-T
lymphocytes has yet to be determined.
In the present study we have employed pharmaco-
logic inhibitors to determine whether PTK andror
PKC activation are requisite steps in the process by
which AK-T lymphocytes lyse tumour target cells.
Herbimycin A, genistein and the erbstatin analogue
 .methyl 2,5-dihydroxycinnamate MDHC were se-
lected as PTK-inhibitors on the basis of the selective
activity which these drugs exhibit against different
w xPTK 8,12,13 . The highly specific PKC-inhibitors
w xcalphostin C 14 and myristoylated PKC pseudosub-
 . w xstrate peptide myr-c PKC 15 , as well as stau-
rosporine, a commonly used but less selective PKC-
w xinhibitor 16 , and phorbol 12-myristate 13-acetate
 . w xPMA desensitization 17 were used to inhibit PKC
activity in AK-T lymphocytes.
2. Materials and methods
2.1. Materials
2.1.1. Mice
 .  bFemale 6–8-week-old C57BLr6 H-2 haplo-
.type mice purchased from Charles River Laboratory
 .Lasalle, Que. were maintained in our animal care
facilities on standard mouse chow and water supplied
ad libitum.
2.1.2. Cell lines, medium, and reagents
RPMI 1640 medium ICN Pharmaceuticals Canada
.Ltd., Montreal, Que. was supplemented with 10 mM
L-glutamine, 100 mgrml streptomycin, 100 Urml
 . penicillin all ICN , and 5% heat-inactivated at 568C
. for 30 min fetal calf serum Gibco BRL, Burlington,
.Ont. . Hereafter, this will be referred to as complete
 dRPMI 1640 medium. P815 mastocytoma cells H-2
.  a .haplotype , YAC-1 lymphoma cells H-2 haplotype
 .and the hybridoma clone FD441.8 producing rat
anti-mouse LFA-1 mAb were obtained from the
American Type Culture Collection, Rockville, MD.
 .The hybridoma clone 145-2C11 producing hamster
 .anti-mouse CD3 mAb 2 was a generous gift from
Dr. J. Bluestone University of Chicago, Chicago,
.IL . All cell lines were maintained by in vitro passage
in complete RPMI 1640 medium. Rabbit antiserum to
mouse asialoGM1 was obtained from Wako Pure
 .Chemicals Richmond, VA . Low-Tox rabbit comple-
ment was supplied by CedarLane Laboratories Ltd
 .Hornby, Ont. . Recombinant human interleukin-2
 .active in the murine system was from Cetus Corp.
 .Emeryville, CA . Activity is expressed as Cetus
Urml assigned on the basis of the bioassay described
in the product literature. Na-CBZ-L-lysine thioben-
 .zylester BLT was purchased from Sigma Chemical
 .  .Co. St. Louis, MO . Dithiobis 2-nitrobenzoic acid
 .was from Boehringer Mannheim Laval, Que. .
MDHC, genistein, and herbimycin A were purchased
from Gibco BRL while PMA, staurosporine and 3-
 .4,5-dimethylthiazol-2-yl -2,5-diphenyltetrazolium
 .bromide MTT were obtained from Sigma Chemical
Co. Calphostin C and myr-c PKC were from Re-
 .search Biochemicals International Natick, MA .
Stock solutions of MDHC, genistein, herbimycin A,
staurosporine, and calphostin C were prepared in
 .dimethyl sulfoxide DMSO; Sigma Chemical Co.
while PMA was dissolved in absolute ethanol. A
stock solution of myr-c PKC was prepared in serum-
free RPMI 1640 medium. All stock solutions were
stored at y208C, and diluted in complete RPMI 1640
medium as required.
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2.2. Experimental procedures
2.2.1. Generation of AK-T lymphocytes
Spleen cells from C57BLr6 mice were depleted of
erythrocytes by osmotic shock and passaged through
a nylon wool column to enrich for T lymphocytes
w x18 . NK cells were removed from the nylon wool-
nonadherent spleen cell preparation by two-step treat-
 .ment with anti-asialoGM1 antiserum 1r40 and
 .Low-Tox rabbit complement 1r12 . To generate
AK-T lymphocytes, the resulting T cell-enriched
preparation typically 91% T cells and -0.1% NK
w x.cells by flow cytofluorimetric analysis 19 was cul-
 6tured in complete RPMI 1640 medium 4–5=10
.cellsrml containing anti-CD3 hybridoma culture su-
 .pernatant 1r40 final dilution plus 50 Urml recom-
binant human interleukin-2. Following 48 h of culture
at 378C in a humidified atmosphere containing 5%
CO , AK-T lymphocytes were collected and washed2
3 times by centrifugation to remove residual anti-CD3
mAb prior to use in experiments.
2.2.2. Cytolytic 51Cr-release assay
 6.Target cells 2–5=10 were incubated for 1 h at
 . w51 x378C with 100 mCi 0.1 ml of Cr sodium chro-
 .mate specific activity 250–500 mCirmg Cr; ICN ,
washed 3 times, and resuspended in complete RPMI
1640 medium at a concentration that would yield
5=103 target cellsrwell. AK-T lymphocytes, drugs
MDHC, genistein, calphostin C, myr-c PKC or stau-
.rosporine or drug vehicle, and radiolabelled target
cells were added sequentially to wells of a 96-well
‘V’-bottom microtiter plate Sarstedt, St. Laurent,
.Que. in a final 0.2 ml volume of complete RPMI
1640 medium. In the case of herbimycin A and PMA
treatments, AK-T lymphocytes were pretreated with
these drugs for 18 h prior to the assay and were then
washed extensively before use. Plates were incubated
for 4 h at 378C in 95% humidified air and 5% CO ,2
centrifuged at 400=g for 5 min, and 0.1 ml volumes
of supernatant were collected from wells. 51Cr re-
leased from lysed target cells was measured by auger
and conversion electron counting with a Wallac 1410
scintillation counter. Percent lysis was calculated ac-
cording to the formula
% lysiss EyS r MyS =100 .  .
where E is the release from experimental samples, S
is the spontaneous release, and M is the maximum
release upon lysis with 10% sodium dodecyl sulfate.
None of the drugs or drug vehicles in the concentra-
tions used in this study had an effect on spontaneous
51Cr release from target cells. Data are presented as
the mean % lysis of triplicate or quadruplicate sam-
 .ples "SD from a representative experiment. Each
experiment was repeated at least 3 times.
2.2.3. Conjugate formation assay
P815 target cells were stained by incubation at
378C for 10 min in the presence of neutral red dye 1
.mgrml in complete RPMI 1640 medium . The dye
stained the cytoplasmic granules of P815 cells, allow-
ing them to be readily distinguished from AK-T
lymphocytes, without affecting cell viability as as-
sessed by trypan blue dye exclusion. Stained P815
cells and AK-T lymphocytes were washed and resus-
pended at 5=106 cellsrml in complete RPMI 1640
 .medium. AK-T lymphocytes 0.1 ml and 0.1 ml of
complete RPMI 1640 medium containing the desired
concentration of genistein, staurosporine or calphostin
C, an equivalent concentration of the drug vehicle, or
 .anti-LFA-1 mAb 2.5 mgrml final concentration
were added to 12=75 mm round-bottom polystyrene
 .tubes Becton Dickinson, Lincoln Park, NJ , followed
10 min later by a 0.1 ml volume of target cells. In the
case of herbimycin A, AK-T lymphocytes were pre-
treated with the drug for 18 h prior to the assay and
then washed extensively before use. The tubes were
centrifuged at 100=g for 5 min and subsequently
incubated for 30 min at 378C in 5% CO . The tubes2
were then placed on ice and the conjugates were
resuspended 5 times using a pipetman set at 200 ml.
Unbound AK-T lymphocytes and AK-T lymphocytes
conjugated to P815 cells were enumerated by micro-
scopic examination in a hemocytometer. At least one
hundred AK-T lymphocytes were counted. Each sam-
ple was counted blind in triplicate. The percentage of
conjugated AK-T lymphocytes was calculated. Each
experiment was performed at least twice.
2.2.4. BLT-esterase assay
To measure BLT-esterase activity released by
AK-T lymphocytes during cytolytic assays, 0.05 ml
of cell-free supernatant was transferred from each
‘V’-bottom well to an empty well in a 96-well flat-
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bottom microtiter plate. Then 0.1 ml of 1 mM dithio-
 .bis 2-nitrobenzoic acid and 0.05 ml of 2 mM BLT
 .substrate both in phosphate-buffered saline were
added to each well. The plate was incubated for 18 h
at room temperature and the absorbance was read at
 .405 nM using a Titertek plate reader ICN . An
absorbance of 0.01 was arbitrarily defined as 1 U of
esterolytic activity. Data are represented as mean
units of esterolytic activity in triplicate samples
 ."SD from an experiment representative of 3 indi-
vidual experiments.
2.2.5. Cell ˝iability assays
51 w x w xCr-release 20 and MTT 21 assays were used
to evaluate the nonspecific toxicity of the PTK- and
PKC-inhibitors used in this study. For 51Cr-release
viability assays, AK-T lymphocytes were loaded with
51 Cr by incubation for 1 h at 378C with 100 mCi 0.1
. w51 x ml of Cr sodium chromate specific activity 250–
.500 mCirmg Cr; ICN , washed 3 times, and resus-
pended in complete RPMI 1640 medium at 106
 .cellsrml. Equal volumes 0.1 ml of AK-T cells and
PTK- or PKC-inhibitors at the desired concentrations
were added to quadruplicate wells of a 96-well ‘V’-
bottom microtiter plate and incubated for 4 h at 378C
in 95% humidified air and 5% CO . After centri-2
fuging the plate at 400=g for 5 min, 0.1 ml volumes
of supernatant were collected from wells and 51Cr-re-
lease was measured as previously described. Percent
viability was calculated according to the formula
% viabilitys 1y DyC r MyC =100 .  .
where D is the release from drug-treated AK-T cells,
C is the release from untreated control AK-T cells,
and M is the maximum release following lysis with
10% sodium dodecyl sulfate. In the case of MTT
viability assays, 105 AK-T cells in a 0.2 ml volume
of complete RPMI 1640 medium were incubated for
4 h at 378C in a 95% humidified atmosphere and 5%
CO with various concentrations of the drugs in2
quadruplicate wells of a 96-well microtiter plate. The
AK-T cells were then washed twice with phosphate
buffered saline and 200 ml of sterile MTT dye di-
luted 1:10 in complete RPMI 1640 medium was
added to each well. AK-T cells were incubated at
378C for another 2 h. After pelleting the AK-T cells
by centrifugation and removing the MTT solution,
100 ml of DMSO was added to each well and,
following thorough mixing, spectrometric absorbance
was measured at 492 nM using a Titertek plate
reader. Data are expressed as % control MTT read-
ings obtained with AK-T cell incubated in complete
RPMI 1640 medium in the absence of PTK or PKC
inhibitors.
2.2.6. Statistical analysis
Statistical comparisons of data were performed
using the Instat statistics program GraphPad Soft-
.ware, San Diego, CA . One-way analysis of variance
and the Bonferroni test was used for multiple com-
parisons while Student’s t-test was used to compare
differences between two different sample groups. P
values less than 0.05 were considered to be statisti-
cally significant.
3. Results
3.1. PTK-inhibitors block AK-T lymphocyte-mediated
lysis of tumour cells
To investigate the role of PTK in AK-T lympho-
cyte-mediated killing of tumour cells, we first evalu-
ated the effect of herbimycin A pretreatment on the
 b .ability of C57BLr6-derived H-2 haplotype AK-T
 dlymphocytes to lyse P815 mastocytoma H-2 haplo-
.type target cells. As shown in Table 1, effector
function was inhibited in a dose-dependent fashion
by herbimycin A pretreatment with nearly complete
inhibition occurring at 2 mM herbimycin A. A com-
parable dose-dependent inhibition of AK-T lympho-
cyte cytolytic activity was obtained in the presence of
MDHC. Genistein at 100 and 50 mM concentrations
was also effective in suppressing AK-T lymphocyte-
mediated cytolysis. Although not shown, similar re-
 a .sults were obtained when YAC-1 H-2 haplotype
lymphoma cells were used instead of P815 cells as
 .targets. The drug vehicle DMSO alone, at appropri-
ate doses, had no significant effect on the cytolytic
 .activity of AK-T lymphocytes data not shown . Ef-
fector cell viability, as determined by MTT and
51Cr-release assays, was not substantially altered in
the presence of the PTK-inhibitors with the exception
of MDHC which, at the highest concentration used,
appeared to cause a slight decrease in AK-T cell
 .viability Table 2 .
( )B.H. Stewart, D.W. HoskinrBiochimica et Biophysica Acta 1356 1997 333–342 337
Table 1
Effect of PTK-inhibitors on the cytolytic activity of AK-T lym-
phocytes
a bDose % Lysis P815"SD
Expt. 1 Expt. 2
 .  .% inhibition % inhibition
 .Herbimycin A mM
0 76"3 55"1
 .  .0.5 27"3 64 24"2 56
 .  .1.0 17"1 78 18"1 67
 .2.0 5"1 93 ND
cSignificance P -0.0001 P -0.0001
 .MDHC mM
0 44"2 34"3
 .1.0 32"3 27 ND
 .  .5.0 20"3 55 25"1 26
 .  .10.0 9"2 80 24"3 29
 .  .20.0 6"1 86 15"2 56
Significance P -0.0001 P -0.0001
 .Genistein mM
0 62"7 51"3
 .  .50.0 51"3 18 31"2 39
 .  .100.0 29"4 50 16"3 63
Significance P -0.0001 P -0.0001
a AK-T lymphocytes were incubated with P815 target cells in the
presence of the indicated concentrations of MDHC or genistein
or, in the case of herbimycin A, were pretreated for 18 h prior to
the cytolytic assay.
b  .% Lysis after 4 h was measured at an effector:target E:T cell
ratio of 50:1 as described in Section 2. NDsnot determined.
c One-way analysis of variance and Bonferroni test.
3.2. PKC inhibition interferes with AK-T lymphocyte
cytolytic effector function
To determine whether PKC activity is required for
AK-T lymphocytes to lyse tumour target cells, we
examined the effect of several PKC-inhibitors on
cytolytic activity against P815 mastocytoma cells.
Data shown in Table 3 demonstrate that, in the
presence of the PKC-inhibitors calphostin C and stau-
rosporine, killing of P815 mastocytoma cells by AK-T
lymphocytes was reduced in a dose-dependent fash-
ion. In addition, we tested the effect of myr-c PKC, a
cell-permeable synthetic peptide corresponding to the
pseudosubstrate motif of PKC-a and -b subtypes
w x15 , on the tumoricidal activity of AK-T cells and
observed a dose-dependent inhibition of P815 cytoly-
sis. Furthermore, overnight exposure of AK-T lym-
Table 2
Effect of PTK-inhibitors on AK-T lymphocyte viability
aInhibitors mM % Control % Viability by
51MTT assay Cr-release
Herbimycin A 1.0 96 99
2.0 92 98
Genistein 50.0 100 100
100.0 100 100
MDHC 10.0 91 97
20.0 67 86
a AK-T lymphocytes were incubated for 4 h with complete RPMI
1640 medium alone or in the presence of increasing concentra-
tions of PTK-inhibitors as described in Section 2.
Table 3
Effect of PKC inhibition on the cytolytic activity of AK-T
lymphocytes
a bDose % Lysis P815"SD
Expt. 1 Expt. 2
 .  .% inhibition % inhibition
 .Staurosporine nM
0 60"2 48"2
 .  .10.0 51"3 18 43"4 10
 .  .25.0 33"1 47 29"2 40
 .  .50.0 14"2 77 13"2 73
cSignificance P -0.0001 P -0.0001
 .Calphostin C mM
0 52"4 71"4
 .  .0.1 17"1 73 51"3 28
 .  .0.25 3"2 95 25"3 65
 .  .0.50 1"1 98 6"1 92
 .  .1.00 1"1 98 1"1 99
Significance P -0.0001 P -0.0001
 .Myr-c PKC mM
0 62"11 42"3
 .  .50.0 30"3 52 15"2 64
 .  .100.0 6"1 90 9"1 79
Significance P -0.0001 P -0.0001
 .PMA mM
0 49"2 16"1
 .  .1.6 2"1 96 3"1 81
dSignificance P -0.0001 P -0.0001
a AK-T lymphocytes were incubated with P815 target cells in the
presence of the indicated concentrations of staurosporine,
calphostin C or myr-c PKC or, in the case of PMA, were
pretreated for 18 h prior to the cytolytic assay.
b % Lysis after 4 h was measured at an E:T cell ratio of 50:1 as
described in Section 2.
c One-way analysis of variance and Bonferroni test.
d Student’s t-test.
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Table 4
Effect of PKC-inhibitors on AK-T lymphocyte viability
aInhibitors mM % Control % Viability by
51MTT assay Cr-release
Staurosporine 0.025 76 95
0.050 76 93
Calphostin C 0.5 90 100
1.0 75 98
Myr-c PKC 50.0 79 86
PMA 1.6 99 100
a AK-T lymphocytes were incubated for 4 h with complete RPMI
1640 medium alone or in the presence of increasing concentra-
tions of PKC-inhibitors as described in Section 2.
phocytes to 1.6 mM PMA prior to their use in
cytotoxicity assays resulted in a nearly complete loss
of cytolytic activity, suggesting an important role for
PKC in AK-T cell-mediated cytolysis since exposure
of lymphocytes to this dose of PMA for extended
periods of time is known to cause a selective loss of
w xPKC activity 17 . We also investigated the effect of
PKC-inhibitors on AK-T lymphocyte killing of YAC-
1 lymphoma cells and obtained similar results data
.not shown . Although not shown, the drug vehicles
alone had no effect on the cytolytic activity of AK-T
lymphocytes. The effect of PKC-inhibitors on effec-
tor cell viability was examined. As detailed in Table
4, all drugs tested, with the exceptions of PMA and
0.5 mM calphostin C, had slight negative effects on
AK-T lymphocyte viability when viability was deter-
mined by MTT assay. On the other, little or no
cytotoxicity due to the PKC-inhibitors was observed
when 51Cr-release was used to assess AK-T cell
viability. In any case, the observed effects on AK-T
lymphocyte viability were of insufficient magnitude
to account for the strong inhibition of cytolytic effec-
tor function by the various PKC-inhibitors when used
at the same or lower concentrations.
3.3. Effector-to-target cell conjugation is not affected
by PTK or PKC inhibition
We next performed conjugation assays to deter-
mine whether PTK andror PKC activation is in-
volved in AK-T lymphocyte binding to tumour cells.
As shown in Table 5, neither PTK- herbimycin A,
. genistein nor PKC-inhibitors calphostin C, stau-
.rosporine , at concentations that were strongly in-
hibitory to AK-T lymphocyte cytolytic activity see
.Tables 1 and 3 , were able to significantly affect
AK-T lymphocyte conjugation to P815 target cells. In
contrast, treatment with anti-LFA-1 mAb, which was
used as a positive control in these experiments, greatly
Table 5
Effect of PTK- and PKC-inhibitors on AK-T lymphocyte binding to P815 target cells
a b cExpt. Treatments % Conjugation"SD Significance
1 Control 17"3
 .Herbimycin A 1 mM 15"2 NS
 .Anti-LFA-1 mAb 2.5 mgrml 8"2 Ps0.0124
2 Control 26"3
 .Genistein 100 mM 25"4 NS
 .Anti-LFA-1 mAb 2.5 mgrml 7"1 Ps0.0005
3 Control 23"3
 .Staurosporine 25 nM 23"3 NS
 .Anti-LFA-1 mAb 2.5 mgrml 8"3 Ps0.0036
4 Control 23"3
 .Calphostin C 0.5 mM 20"1 NS
 .Anti-LFA-1 mAb 2.5 mgrml 11"2 Ps0.0052
a AK-T lymphocytes were incubated with P815 target cells in the presence of the drug vehicle alone or the indicated concentrations of
genistein, staurosporine or calphostin C or, in the case of herbimycin A, AK-T cells were pretreated with the drug as described in Section
2. The addition of anti-LFA-1 mAb to otherwise untreated AK-T lymphocytes and P815 target cells served as a positive control.
b  .Results from a representative experiment are expressed as mean "SD percentage of AK-T lymphocytes binding to P815 target cells.
c Determined by Student’s t-test; NSsnot significant.
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reduced AK-T lymphocyte binding to P815 cells.
These data indicate that PTK and PKC inhibition
disrupts processes which occur during the postbind-
ing stage of AK-T lymphocyte-mediated cytolysis.
3.4. PTK and PKC inhibition abolishes BLT esterase
release by AK-T lymphocytes
Granule exocytosis, which is a major mechanism
by which killer lymphocytes deliver the ‘lethal hit’ to
target cells, is an important postbinding event in
w xAK-T lymphocyte-mediated lysis of tumour cells 19 .
We therefore tested the effect of PTK and PKC
inhibition on granule exocytosis, as determined by
the release of BLT esterase activity which co-local-
izes with cytolytic effector molecules such as per-
forin within the cytoplasmic granules of AK-T lym-
w xphocyte 11 . AK-T lymphocytes pretreated with her-
bimycin A to inactivate PTK, or AK-T lymphocytes
Fig. 1. Effect of PTK and PKC inhibition on granule exocytosis
by AK-T lymphocytes. A. AK-T lymphocytes pretreated with the
 .drug vehicle or the PTK-inhibitor herbimycin A 1 mM for 18 h
prior to the assay were washed and added to P815 target cells at
an E:T ratio of 50:1. B. AK-T lymphocytes were combined with
P815 target cells at an E:T ratio of 50:1 in the presence or
 .absence of the PKC-inhibitor calphostin C 0.5 mM . In both
cases, after 4 h the release of BLT esterase activity was measured
as described in Section 2. Statistical significance was determined
). )).by Student’s t-test; denotes P s0.0004, denotes P s
0.0077.
treated with calphostin C to block PKC activity were
incubated for 4 h with P815 target cells and the
subsequent release of BLT esterase activity was mea-
sured in a colorimetric BLT esterase assay. We ob-
served that release of BLT esterase activity by AK-T
lymphocytes was reduced by almost 90% when PTK
 .  .Fig. 1A or PKC Fig. 1B activity was inhibited,
indicating that PTK and PKC are involved in the
release of cytoplasmic granule contents by AK-T
lymphocytes.
4. Discussion
The biochemical events involved in recognition
and lysis of virally-infected or transformed target
cells by antigen-specific CTL have been well charac-
terized. Triggering of antigen-specific CTL through
the T cell receptorrCD3 complex leads to a cascade
of biochemical events involving PTK and PKC acti-
w xvation, and culminating in target cell lysis 22,23 .
However, the signal transduction pathways involved
in the T cell receptor-independent recognition and
lysis of tumour target cells by nonspecific killer T
lymphocytes induced with anti-CD3 mAb have not
yet been defined. The present study provides evi-
dence that protein tyrosine phosphorylation and PKC
activation are important steps in AK-T lymphocyte-
mediated killing of tumour target cells, because either
PTK or PKC inhibition by pharmacologic inhibitors
caused a marked reduction in the tumoricidal activity
of AK-T lymphocytes. For the most part, neither the
PTK- nor the PKC-inhibitors employed in our experi-
ments had any substantial effect on the viability of
AK-T lymphocytes over the course of 4-hr cytolytic
51Cr-release assays. We used two different assays to
evaluate AK-T cell viability following exposure to
PTK- or PKC-inhibitors: the 51Cr-release permeabil-
ity assay, which measures alterations in cellular
w xmembrane integrity 20 ; and the MTT assay which
measures changes in the function of mitochondrial
w xdehydrogenases 21 . Both assays are considered to
be acceptable methods of determining cell viability in
w xmammalian cell culture systems 24 . Furthermore,
AK-T lymphocytes conjugated normally to tumour
target cells and released dramatically less BLT es-
terase in the presence of PTK- or PKC-inhibitors.
Nonspecific cytotoxicity caused by the PTK- and
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PKC-inhibitors would be expected to alter effector
cell adhesion to target cells and, if anything, increase
BLT esterase secretion as cell membrane permeabil-
ity was compromised. In agreement with previous
reports that PTK- and PKC-inhibitors have minimal
w xeffects on lymphocyte viability 11,25 , we conclude
that diminished killing of tumour cells in the pres-
ence of PTK- and PKC-inhibitors was not due to
nonspecific toxic effects of the drugs on the AK-T
cells.
The pharmacologic approach which we have taken
to investigate the requirement for PTK and PKC
activity in AK-T lymphocyte effector function is well
established. Herbimycin A, genistein, and MDHC
have been widely used to inhibit the activity of PTK
involved in a number of receptor-associated T cell
w xsignaling pathways 11,26–28 . Previous studies have
demonstrated that PKC signaling in T lymphocytes is
intact in the presence of the PTK inhibitors used in
w x w xour study 26,29–31 . For example, Osorio et al. 30
observed that herbimycin A does not affect the up-
regulation of CD25 expression induced through the
w xactivation of PKC by phorbol ester 32 . Similarly,
genistein has no effect on PMA-induced expression
w xof CD69 by T cells 31 , which is a PKC-dependent
w xevent 33 . Herbimycin A degrades src-family PTK
without affecting the serinerthreonine kinases, PKC
w xand c-raf 26 . On the other hand, genistein and
w xMDHC are competitive PTK-inhibitors 12,13 and
must therefore be present during the cytotoxicity
assay to mediate PTK inhibition, raising the possibil-
ity that these drugs might also somehow affect the
tumour target cells. However, since herbimycin A
was not present during the cytotoxicity assay, any
possible untoward effect of PTK inhibition on tumour
cell susceptibility to lysis can be discounted. Our data
therefore indicate that AK-T lymphocyte-associated
protein tyrosine phosphorylation is critical for tumo-
ricidal activity.
A number of recent studies have employed
calphostin C and staurosporine to inhibit PKC-depen-
dent signaling pathways in T lymphocytes
w x11,28,34,35 . PTK signaling in T cells is intact in the
presence of either staurosporine or calphostin C be-
cause neither drug affects PTK-dependent Ca2q mo-
w xbilization responses 34 or IgD receptor expression
w x28 . Staurosporine is a commonly used PKC-inhibi-
tor which acts by targeting the proteolytically gener-
w xated catalytic domain of PKC 16 . However, stau-
rosporine also inhibits protein kinase A and protein
kinase B because of the striking degree of homology
which exists between these protein kinases and PKC
w w xxreviewed in 36 . It was therefore possible that the
observed inhibitory effect of staurosporine on AK-T
lymphocyte function could be attributed at least in
part to the nonspecific inhibition of other protein
kinases. In order to exclude this possibility, we also
used calphostin C and myr-c PKC, both of which are
w xhighly selective inhibitors of PKC 14,15 . Calphostin
C targets the regulatory domain of PKC, which is
w xdistinct from those of other protein kinases 37 .
Myr-c PKC interacts with the substrate binding site
in the catalytic domain of PKC, thereby keeping the
w xenzyme in its inactive state 15 . As with stau-
rosporine, an inhibitory effect on the cytolytic effec-
tor function of AK-T lymphocytes was observed in
the presence of both calphostin C and myr-c PKC.
Since it is well established that PMA-sensitive PKC
isoforms are downregulated in T lymphocytes by
 . w xovernight treatment 16 h with PMA 17,38 , we also
used long-term exposure to PMA to cause a selective
loss of PKC activity in AK-T lymphocytes prior to
their use in cytotoxicity assays. The subsequent re-
duction in the tumoricidal activity of AK-T lympho-
cytes which we observed suggests that reduced cytol-
ysis in the presence of PKC-inhibitors is not due to
any untoward effect of the PKC-inhibitors on tumour
cell susceptibility to lysis. Taken together, our data
indicate that PKC activity is required for AK-T lym-
phocytes to lyse tumour target cells.
We also investigated the effect of PTK and PKC
inhibition on binding and postbinding stages in the
lytic process. A visual binding assay was employed
to determine whether the suppressive effect of PTK
andror PKC inhibition on AK-T lymphocyte effector
function could be attributed to reduced conjugate
formation between AK-T lymphocytes and P815 tu-
mour cells. Antigen-specific CTL adhesion to al-
loantigen-bearing target cells has been reported to
w xdepend on protein tyrosine phosphorylation 39 and
may, to a lesser extent, also involve PKC activation
w x23,40 . However, inhibition of PTK or PKC activity
by treatment with pharmacologic inhibitors, at doses
which prevented tumour cell lysis in our cytotoxicity
assays, had no discernable effect on the ability of
AK-T lymphocytes to conjugate to P815 target cells.
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We conclude that PTK and PKC activation is re-
quired during the postbinding stage of AK-T lympho-
cyte-mediated lysis. Interestingly, anti-LFA-1 mAb
employed as a positive control in our binding as-
.says caused a 52–77% inhibition in conjugate for-
mation, indicating that the interaction of LFA-1 with
its ligands plays an important role in AK-T lympho-
cyte binding to P815 mastocytoma cells. In addition,
 .activation of PTK s associated with LFA-1 has re-
cently been implicated in triggering NK cytotoxicity
w x41 , suggesting a possible role for LFA-1 in trigger-
ing AK-T lymphocytes to kill tumour cells.
We observed that inhibition of either protein tyro-
sine phosphorylation or PKC activation resulted in
the virtual abrogation of tumour cell-induced granule
exocytosis by AK-T lymphocytes. Other investigators
who have examined the role of PTK and PKC activa-
tion in antigen-specific CTL, as well as NK cell
effector function have reported similar findings
w x22,23,42,43 , suggesting that the biochemical events
involved in the postbinding stage of nonspecific AK-T
lymphocyte-mediated lysis of tumour cells may be
common to the function of other cytolytic effector
cells. Furthermore, our data suggest that PTK andror
PKC activation may be obligatory steps in the post-
binding signal transduction cascade which activates
the cytolytic machinery of AK-T lymphocytes. PTK
andror PKC may also be directly involved in the
release of granule contents by AK-T cells, as has
been proposed for PTK in granule secretion by neu-
w x w xtrophils 44 and antigen-specific CTL 22 . Unfortu-
nately, the pharmacologic approach that we have
employed does not allow us to differentiate between
PTK andror PKC regulation of early or distal events
in the postbinding stage of AK-T lymphocyte-media-
ted lysis. Nevertheless, since AK-T lymphocytes de-
pend primarily on granule-associated cytolytic
w xmolecules to mediate P815 killing 19 , our findings
indicate the protein tyrosine phosphorylation and PKC
activation play important roles in regulating the pro-
cess by which AK-T lymphocytes deliver the ‘lethal
hit’ to tumour target cells.
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